Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines Guidelines

  

Authors:	Lacouture, M. E.; Sibaud, V.; Gerber, P. A.; van den Hurk, C.; Fernández-Peñas, P.; Santini, D.; Jahn, F.; Jordan, K.; ESMO Guidelines Committe
Title:	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
Keywords:	prednisone; sorafenib; doxorubicin; erlotinib; fluorouracil; sunitinib; advanced cancer; skin toxicity; capecitabine; antineoplastic agent; clinical practice; melanoma; incidence; practice guideline; cetuximab; docetaxel; panitumumab; pruritus; patient care; acne; gefitinib; pazopanib; hydrocortisone; isotretinoin; axitinib; doxycycline; hand foot syndrome; minocycline; alopecia; dapsone; lapatinib; pertuzumab; papular rash; supportive care; etretin; chemotherapy-induced alopecia; hand-foot syndrome; alclometasone; vemurafenib; acneiform rash; dabrafenib; trametinib; afatinib; dermatological toxicities; dacomitinib; lenvatinib; human; priority journal; article; binimetinib; necitumumab; encorafenib; cobimetinib; osimertinib; drug-induced pruritus
Journal Title:	Annals of Oncology
Volume:	32
Issue:	2
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2021-02-01
Start Page:	157
End Page:	170
Language:	English
DOI:	10.1016/j.annonc.2020.11.005
PUBMED:	33248228
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098109577&doi=10.1016%2fj.annonc.2020.11.005&partnerID=40&md5=351f4ad17f1aca7cf7392ed9a01e1a54
Notes:	Article -- Export Date: 1 February 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/176054